GLMD Stock Price, Chart, Stats & News

Galmed Pharmaceuticals Ltd.
Save
3.13M
Market cap
–
Current P/E
–
Forward P/E
GLMD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.31% |
ROE | -47.78% |
D/E | – |
Interest coverage ratio | -15.70x |
GLMD valuation
P/E | – |
P/S | – |
P/B | 0.14x |
P/CF | -0.43x |
P/FCF | -0.44x |
P/OCF | -0.43x |
PEG | -0.01x |
EV multiple | -0.86x |
About
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Similar securities
Based on sector and market capitalization
Report issue











